These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20062993)

  • 1. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
    Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.
    Fakih MG; Groman A; McMahon J; Wilding G; Muindi JR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):743-51. PubMed ID: 22020318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
    Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
    Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
    Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
    Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
    Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
    Fakih MG; Pendyala L; Fetterly G; Toth K; Zwiebel JA; Espinoza-Delgado I; Litwin A; Rustum YM; Ross ME; Holleran JL; Egorin MJ
    Clin Cancer Res; 2009 May; 15(9):3189-95. PubMed ID: 19383814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
    Leichman CG; Lenz HJ; Leichman L; Danenberg K; Baranda J; Groshen S; Boswell W; Metzger R; Tan M; Danenberg PV
    J Clin Oncol; 1997 Oct; 15(10):3223-9. PubMed ID: 9336359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
    Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
    Grimminger PP; Shi M; Barrett C; Lebwohl D; Danenberg KD; Brabender J; Vigen CL; Danenberg PV; Winder T; Lenz HJ
    Pharmacogenomics J; 2012 Oct; 12(5):404-11. PubMed ID: 21788964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
    Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
    Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.